posted on 2025-05-07, 09:59authored byAC Jaschke, C Howlin, J Pool, YD Greenberg, R Atkinson, A Kovalova, E Merriam, I Pallás-Ferrer, S Williams, C Moore, K Hayden, C Allison, H Odell-Miller, S Baron-Cohen
Following the publication of the original article [1], the authors identified that the funding statement was incomplete. The funding is given below: The incorrect funding statement is: This research has been funded by the Rosetrees Trust, the Stoneygate Trust and the Autism Centre for Excellence (ACE). The correct funding statement is: This research has been funded by the Rosetrees Trust, the Stoneygate Trust and the Autism Centre for Excellence (ACE). SBC received funding from the Wellcome Trust 214,322\Z\18\Z. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777,394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. SBC also received funding from the Autism Centre of Excellence, SFARI, the Templeton World Charitable Fund and the MRC. All research at the Department of Psychiatry in the University of Cambridge was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research Collaboration East of England. The original article [1] has been corrected.